Abstract: Antibiotic A-7413 complex, comprising a major microbiologically active factor A, and minor active factors B, C, and D, is produced by fermentation of Actinoplanes sp. NRRL 8122. The individual factors are isolated and separated by extraction and chromatography. The A-7413 antibiotics are antibacterial agents. The A-7413 complex and A-7413 antibiotic compounds are also useful as growth-promoting agents and in the control of dental caries and acne.

Abstract: A new antibacterial compound, DC-11 is produced by fermentation of a microorganism belonging to the genus Micromonospora. The antibiotic is accumulated in the culture medium and is isolated therefrom.

Abstract: A novel antibiotic substance, named "Mycoplanecin", of presently unknown structural formula, is produced by cultivating a Mycoplanecin-producing microorganism of the genus Actinoplanes, especially the Actinoplanes nov. sp. Strain No. 41042, NRRL No. 11462.

Abstract: Disclosed and claimed is an improved fermentation process for preparing the known antibiotic U-43,120, herein referred to as paulomycin. Also disclosed and claimed are the novel and useful antibiotics paulomycin A and paulomycin B.

Abstract: Novel substance M-9337 obtained by culturing Streptomyces antihaemolyticus is effective as an antitoxic substance for neutralizing toxins discharged from streptococci, staphylococci, tetanus or the like.

Abstract: A novel antibiotic substance, named "Mycoplanecin", of presently unknown structural formula, is produced by cultivating a Mycoplanecin-producing microorganism of the genus Actinoplanes, especially the Actinoplanes nov. sp. Strain No. 41042, NRRL No. 11462.

Abstract: Novel antibiotic U-62,162 producible in a fermentation under controlled conditions using a man-made biologically pure culture of the microorganism Streptomyces verdensis, Dietz and Li sp.n., NRRL 12256. This antibiotic is strongly active against various Gram-positive bacteria, for example, Staphylococcus aureus. Thus, antibiotic U-62,162 can be used in various environments to eradicate or control such bacteria.

Abstract: The specification describes novel antibiotic NCS-C and its free acid salts. Their antimicrobial effects are at least comparative with neocarzinostatin, and, against some microorganisms, superior. The novel antibiotic NCS-C or its free acid salt is prepared either by culturing an NCS-C yielding microorganism belonging to the Streptomyces family in a culture medium, separating the culture medium into bacterial bodies and culture filtrate, and extracting the culture filtrate with a water-immiscible polar organic solvent under acidic conditions, or by decomposing neocarzinostatin under acidic conditions and extracting resultant free acid salt with a polar organic solvent.

Abstract: Antibiotic Actinomadura-L-31 A has the characteristics as the hydrochloride salt:appearance: white or pale yellow powdermelting point: non-clear melting pointspecific rotation: [.alpha.].sub.D.sup.25 -34.degree. (C: 0.5, pH: 7.5 water)elementary analysis: (found) C: 51.71%; H: 6.23%; O: 21.03%; N: 13.94%; S: 5.82%; Cl: 1.17%constitutive aminoacids: aspartic acid; glutamic acid; glycin; valine; phenylalanine; histidine; leucine; tryptophanultraviolet absorption spectrum: FIG. 1, maximum absorption:280 nm: E.sub.1 cm.sup.1% =45.2290 nm: shoulder E.sub.1 cm.sup.1% =38infrared spectrum: FIG. 2, absorption (cm.sup.-1) 3350, 3050, 2950, 1660, 1530, 1430, 1395, 1340, 1255, 1235, 1100, 745, 700Antibiotic Actinomadura-L-31 B has the characteristics as the hydrochloride salt:appearance: white to pale yellow powdermelting point: non-clear melting pointspecific rotation: [.alpha.].sub.D.sup.25 -26.degree. (C: 0.5; pH: 7.5 water)elementary analysis: (found) C: 51.10%; H: 6.34%; O: 20.75% N: 14.81%; S: 5.91%; Cl: 1.

Abstract: A new antibiotic SF-1130-x.sub.3 substance is produced by cultivating a microorganism Streptomyces myxogenes SF-1130 (deposited under FERM-P. 676 and ATCC 31305) in a liquid culture medium under aerobic conditions, and this antibiotic may be isolated from the fermentation broth of said microorganism and is useful as an inhibitor to .alpha.-glucosidase and saccharase. Besides, this antibiotic, when orally given, is useful as a drug for suppressing an elevation in the level of blood sugar in living animals which have taken starch and/or sugars.

Abstract: Prodn. of FR-900129 comprises culturing a Streptomyces n. 4012 category which is analogous to Streptomyces misakiensis and Steptomyces aburaviensis, i.e. Streptomyces avellaneus No. 4012, at 25.degree. C. to 30.degree. C. during 50 to 100 hours in a culture medium which consists of a carbon source (e.g. glucose, fructose, glycerin, starch, galactose, maltose, dextrin), an organic or inorganic nitrogen source (e.g. yeast extract, peptone, cottonseed cake, soyabean powder, cornsteep liquor, dry yeast, ammonium nitrate, ammonium sulphate, ammonium phosphate, urea and amino acid) and an inorganic salt (e.g. calcium carbonate, sodium phosphate, potassium phosphate, sodium chloride, potassium chloride, magnesium salt and copper salt). The produced FR-900129 is isolated by a collecting step, a purifying step, a vacuum condensation step, a freeze-drying step, a pH adjusting step, a cationic, anionic or nonionic resin treating step, an active carbon adsorption step and a crystallizing and recrystallizing step.

Abstract: The antibiotic MSD A63A, having antibacterial and growth-permittant activity, is produced by fermentation of Streptoverticillum hiroshimense MA4845 (ATCC 31586), in a suitable nutrient media.

Abstract: Novel antibiotic U-60, 394 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces woolenses, Dietz and Li sp.n., NRRL 12113. This antibiotic is strongly active against various Gram-positive bacteria, for example, Staphylococcus aureus and Streptococcus hemolyticus. It is also strongly active against the Gram-negative bacterium Streptococcus pneumoniae. Thus, antibiotic U-60, 394 can be used in various environments to eradicate or control such bacteria.

Abstract: The present invention relates to a glycopeptide antibiotic arbitrarily designated as A/16686 antibiotic, and to its physiologically-acceptable acid addition salts. Antibiotic A/16686 free base, and its acid addition salts are antibacterial agents, especially active against grampositive microorganisms. The process for producing antibiotic A/16686 by culturing a novel strain of the Antinoplanes genus, designated as Actinoplanes sp. ATCC 33076, is a further object of the present invention.

Abstract: A novel anthracycline antibiotic complex, fragilomycin complex, is produced by the cultivation of a fermentation broth containing Streptosporangium fragilis Shearer sp. nov. ATCC 31519 microorganisms in an aqueous nutrient medium under submerged aerobic conditions. The fragilomycin complex and its major bioactive component, fragilomycin A, exhibit antibiotic activity.

Abstract: A process for preparing the antibiotic U-59,760. The process is a microbiological process using a biologically pure culture of the novel microbe Saccharopolyspora hirsuta strain 367, NRRL 12045. The antibiotic produced by the process is active against various microorganisms, for example, Staphylococcus aureus, Streptococcus pyogenes, and Klebsiella pneumoniae. Thus, antibiotic U-59,760 can be used in various environments to eradicate or control such bacteria.

Abstract: Antibiotic A-33853 is produced by submerged, aerobic fermentation of a new Streptomyces sp. NRRL 12068. The antibiotic has shown antibacterial activity against Staphylococcus and Streptococcus species which are penicillin resistant. In addition, the antibiotic has shown antiviral and antitrichomonal activity in vitro.

Abstract: A novel microorganism species belonging to the genus Micromonospora, i.e. Micromonospora sp. A 11725 is found to be capable of producing novel macrolide antibiotics A 11725 I, A 11725 II and A 11725 III. Novel antibiotics A 11725 Ia and A 11725 IIa are also found to be derived by chemical modification of the antibiotics A 11725 I and A 11725 II, respectively. All of these antibiotics or salts thereof exhibit excellent antibacterial and anti-mycoplasmal activities against various microorganisms such as Staphylococcus or Mycoplasma, and therefore useful for various purposes including medicaments.

Abstract: Antibiotics CP-54,715 and CP-54,716, identified by their analytical characteristics, are produced by fermentation of a new microbial species Catenuloplanes jaonicus in a new genus Catenuloplanes and are active against gram-positive and anaerobic infections.

Abstract: Antibiotic A-39183 complex, comprising microbiologically active, related factors A, B, C, D, and E, is produced by submerged, aerobic fermentation of a new microorganism Streptomyces sp., NRRL 12049. The A-39183 antibiotics are closely related antibiotics. The individual A-39183 factors are separated by chromatography. The A-39183 factors are antibacterial agents which have activity against Staphylococcus and Streptococcus species that are penicillin resistant. The A-39183 factors are also active against both gram-positive and gram-negative anaerobic bacteria, and are ionophores.

Abstract: Inhibitor for the glycoside hydrolases of the digestive tract, more particularly of the pancreatic .alpha.-amylase produced by fermentation of the specific microorganism Streptomyces tendae, strain 4158, as well as the variants and mutants thereof, the microbe strain per se and processes for the isolation of the inhibitor and for its purification.

Abstract: The invention relates to a novel metabolite, M.139603, of the empirical formula C.sub.35 H.sub.53 O.sub.8 Na, which is obtained from the aerobic fermentation of a novel Streptomyces species, NCIB 11426, and to the corresponding free acid form thereof, C.sub.35 H.sub.54 O.sub.8. M.139,603 reduces the proportion of methane produced by the "digestion" of food in the rumen of ruminant animals and increases the proportion of propionate to acetate in the rumen contents. The compound is therefore useful for increasing the growth rate of ruminant animals, and/or for increasing their efficiency of food conversion. The compound also possesses activity against Gram positive micro-organisms, and against coccidia, for example Eimeria tenella.

Abstract: A herbicidally active compound of the empirical formula C.sub.10 H.sub.14 N.sub.6 O.sub.3, exhibiting substantially the IR KBr-absorption spectrum shown in FIG. 2, is produced by aerobic culturing of a micro-organism of the family of the Actinoplanaceae under aerobic conditions in a nutrient medium which contains an assimilable carbon source, at least one assimilable nitrogen source and mineral salts, at a pH of 6 to 8 and a temperature of 20.degree. to 40.degree. C.

Abstract: The invention relates to the provision of an antimicrobial antibiotic obtained by culturing Actinoplanes strain ATCC 31440 under aerobic conditions in the presence of sources of carbon and nitrogen and in the presence of trace amounts of minerals. In addition to their use as antimicrobials, the antibiotics of the invention can be used for improving the growth and feed utilization in animals.

Abstract: A new antibiotic designated as auromomycin is prepared from the culture broth of Streptomyces macromomyceticus, a macromomycin-producing strain, as yellow crystals. Auromomycin is recovered in pure form from the culture broth by using hydrophobic chromatography with Octyl Sephalose CL-4B or Phenyl Sepharose CL-4B.

Abstract: Antibiotic acanthomycin (U-53,827) produced by the controlled fermentation of the microorganism Streptomyces espinosus subsp. acanthus, NRRL 11081. This antibiotic and its base addition salts are active against Gram-positive bacteria. Accordingly, they can be used in various environments to eradicate or control such bacteria.

Abstract: Novel antibiotic U-59,761 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Saccharopolyspora hirsuta strain 367, NRRL 12045. This antibiotic is active against various microorganisms, for example, Staphylococcus aureus, Streptococcus pyogenes, Sarcina lutea, Klebsiella pneumoniae, Mycobacterium avium, and Bacteroides fragilis. Thus, antibiotic U-59,761 can be used in various environments to eradicate or control such bacteria.

Abstract: Antibiotic substances named saframycins A, B, C, D and E having antibacterial activity and activity against transplantable tumors. It is produced by cultivation of Streptomyces lavendulae strain No. 314.

Abstract: New antibiotic, SF-2052 substance is produced by cultivating a microorganism, Dactylosporangium matsuzakiense SF-2052 now deposited under FERM-P 4670 or ATCC No. 31570 in a liquid culture medium under aerobic conditions, and this antibiotic may be isolated from the culture broth by conventional method and is useful as antibacterial agent.

Abstract: An anti-tumor substance which is not only heatstable but also has low inflaming and pain-inducing properties and low pyrogenic activity is disclosed. The substance is prepared by disrupting cells of bacteria belonging to hemolytic streptococci, extracting from the disrupted material a water-insoluble substance and treating the substance with one or more proteases and, optionally, with one or more nucleases.

Abstract: This invention relates to a novel antibiotic mixture and to the process for its production. This antibiotic mixture comprises a family of new antibiotic substances which may be separated and isolated as individual components.These antibiotic substances are referred to herein as antibiotic 8327 factor A, antibiotic 8327 factor B and antibiotic 8327 factor C.Antibiotic 8327 factor A is in turn a mixture of three fractions which will be referred to herein as teichomycin A.sub.1, teichomycin A.sub.2 and teichomycin A.sub.3. The novel antibiotic mixture is obtained by cultivation of strain Actinoplanes teichomyceticus nov. sp. ATCC 31121.

Abstract: The antibiotics MSD 890A.sub.1 and MSD 890A.sub.3 and pharmaceutically acceptable salts thereof (hereinafter referred to as antibiotics 890A.sub.1 and 890A.sub.3) are active against both gram-positive and gram-negative bacteria. The antibiotics are produced by growing species of Streptomyces on suitable fermentation media.

Abstract: Ravidomycin is produced by culturing Streptomyces ravidus NRRL 11,300 in an aqueous nutrient medium. Ravidomycin is useful as an antibacterial agent. Methods for its preparation and use are disclosed.

Abstract: The present invention relates to a method of cultivation and extraction of multhiomycin, an antibiotic, and relates also to a veterinary medicine containing multhiomycin as an effective ingredient and more particularly, the present invention provides a method for obtaining multhiomycin by cultivating a multhiomycin-producing fungus such as Streptomyces sp. 8446-CC1 belonging to genus Streptomyces in a culture medium containing a sulfur-containing amino acid and treating the culture medium with a mixed solvent of alcohols and halogenated hydrocarbons or ketones and provides a medicine for promoting growth of animals and preventing various kinds of diseases of animals which contains multhiomycin as an essential component.

Abstract: The present invention relates to a new composition designated as AM-1042 or asukamycin. AM-1042 has an antibiotic activity upon Gram-positive bacteria and Eimeria, and its acute toxicity (LD.sub.50 ' ip.) in mice was 48.5 mg./kg. AM-1042 has an excellent therapeutical effect on various infectious diseases caused by a parasite of Gram-positive bacteria and Eimeria. AM-1042 has been confirmed to be distinguishable from known antibiotics such as e.g. amicetin B, azomycin and manumycin. AM-1042 is produced by fermentation of a microorganism belonging to the genus Streptomyces and capable of producing AM-1042. A composition capable of preventing and curing coccidiosis of poultry containing AM-1042 as active ingredient.

Abstract: New antibiotics, SF-2050 substance and SF-2050B substance are produced by cultivating a microorganism Streptomyces sp. SF-2050 now deposited under FERM-P 4358 and under ATCC. 31450 in a liquid culture medium under aerobic conditions, and these antibiotics may be isolated from the fermentation broth and useful as an antibacterial agent. These antibiotics have an activity inhibitory to .beta.-lactamase.

Abstract: Antibiotics active against gram positive bacteria are produced from Microellobosporia brunea nov. Sp. King 1977.

Abstract: Substance SF-1739 derivatives, Substance SF-1739 HP, Substance SF-1739 HP-C, Substance SF-1739 HP-F, Substance SF-1739 HP-3 and Substance SF-1739 HP-5, the physico-chemical properties of which derivatives are described in the specification; processes for preparing such SF-1739 derivatives; and antimicrobial compositions containing at least one of the said Substance SF-1739 derivatives.

Abstract: Novel antimicrobial substance C-3603 was obtained from the culture of Streptococcus mutans C-3603, FERM-P No. 4128, ATCC No. 31383. The novel antimicrobial substance C-3603 shows a high antimicrobial activity against a variety of gram-positive bacteria, particularly cariogenic bacteria in the oral cavity and it is expected for the utilization to prevent oral infectious diseases, particularly dental caries.

Abstract: An antibiotic SF-1942 substance produced by cultivating an SF-1942 substance producing strain of the genus Streptomyces in a nutrient medium under aerobic conditions to produce and accumulate the SF-1942 substance in the nutrient medium and isolating the SF-1942 substance from the fermentation broth followed by purification and a process for the production of the antibiotic SF-1942 substance. The SF-1942 substance is effective as an antimicrobial agent and an antitumor agent against Sarcoma 180 tumor cells in mice.

Abstract: New antibiotic substances named substance No. 17927A.sub.2 and substance No. 17927A.sub.1 produced by cultivation of substances No. 17927A.sub.2 and No. 17927A.sub.1 -producing microorganisms belonging to the genus Streptomyces as well as pharmaceutically-acceptable salts thereof. They have broad antibacterial activities and also .beta.-lactamase inhibitory action so that they show synergistic actions with known penicillins and cephalosporins.

Abstract: Novel oligosaccharide substances, TAI-A and TAI-B, possessing a strong inhibitory activity to amylase and invertase are obtained by inoculating a seed of the strain of Streptomyces calvus TM-521 into aqueous nutrient medium, cultivating this with shaking or by a submerged culture method with aeration, and separating the produced amylase inhibitors TAI-A and TAI-B from the cultured broth.

Abstract: The present invention relates to new compound nanaomycin A and derivatives thereof represented by general formula: ##STR1## in which (a) R is H and R' is OH (nanaomycin A),(b) R is H and R' is NH.sub.2 (nanaomycin C),(c) R is COCH.sub.3 and R' is CH (acetylnanaomycin A), and(d) R is H and R' is OCH.sub.3 (nanaomycin A methyl ester).Nanaomycin A is a new compound of quinone type and its acute toxicity (LD.sub.50, intra-penetrial injection) in mice is 28.2 mg/Kg. Nanaomycin A and derivatives thereof are active on Gram-positive bacteria, trichophyton and mycoplasma and are useful as a medicament for humans and animals. Nanaomycins A and C are produced by culturing a nanaomycin-producing strain belonging to the genus Streptomyces aerobically in a medium to accumulate nanaomycins A and C in the cultured broths. The derivatives acetylnanaomycin A and nanaomycin A methyl ester have similar properties to those of nanaomycin A.

Abstract: The present invention relates to new compound designated as nanaomycin B represented by general formula: ##STR1## Nanaomycin B is a quinone type and is active on mycoplasma, Gram-positive bacteria and trycophyton. This compound is useful as a medicament for infectious diseases of humans and animals caused by a parasite of trichophyton or mycoplasma etc. The acute toxicity (LD.sub.50, intra-penetrial injection) in mice of this compound is 169 mg/kg. Nanaomycin B is produced by fermentation in which a nanaomycin-producing strain belonging to the genus Streptomyces is cultured in a medium under aerobic conditions and the accumulated nanaomycin B in the cultured broths is recovered therefrom.